Veit J. Erpenbeck

3.6k citations

41 papers · 1.7k indexed · h-index 21

Immunology and Allergy top 1%
- Allergic Rhinitis and Sensitization 16
Physiology top 2%
- Asthma and respiratory diseases 25
Immunology top 5%
- IL-33, ST2, and ILC Pathways 9
- Mast cells and histamine 3
Dermatology top 2%
- Contact Dermatitis and Allergies 3
Rheumatology top 5%
Surgery
- Eosinophilic Esophagitis 5
Pulmonary and Respiratory Medicine
- Respiratory and Cough-Related Research 4
Molecular Biology
- Receptor Mechanisms and Signaling 4

Co-authors: Norbert Krug Jens M. Hohlfeld Armin Braun Thomas Tschernig Jörg Köhl Janice Canvin Stephen T. Holgate William W. Busse
Cited by: Immunology and Allergy Physiology Immunology
Partner nations: Switzerland Germany United States

In The Last Decade

Veit J. Erpenbeck

39 papers receiving 1.6k citations

Peers

Countries citing papers authored by Veit J. Erpenbeck

Since Specialization

Citations

This map shows the geographic impact of Veit J. Erpenbeck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Veit J. Erpenbeck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Veit J. Erpenbeck more than expected).

Fields of papers citing papers by Veit J. Erpenbeck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Veit J. Erpenbeck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Veit J. Erpenbeck. The network helps show where Veit J. Erpenbeck may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Veit J. Erpenbeck, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Veit J. Erpenbeck Line = papers co-authored together Veit J. Erpenbeck links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The Roles of Type 2 Cytotoxic T Cells in Inflammation, Tissue Remodeling, and Prostaglandin (PG) D2 Production Are Attenuated by PGD2 Receptor 2 Antagonism Wentao Chen,Jian Luo,Ye Yuan,Ryan Hoyle,Wei Liu,Rowie Borst,Shamsah Kazani,Eric A. Shikatani,Veit J. Erpenbeck,Ian Pavord,Paul Klenerman,David A. Sandham,Luzheng Xue	2021	11
2	Prostaglandin D2 metabolites activate asthmatic patient-derived type 2 innate lymphoid cells and eosinophils via the DP2 receptor Saskia Carstensen,Christina Gress,Veit J. Erpenbeck,Shamsah Kazani,Jens M. Hohlfeld,David A. Sandham,Meike Müller	2021	8
3	Increased type 2 inflammation post rhinovirus infection in patients with moderate asthma Thomas Southworth,Caroline Pattwell,Naimat Ullah Khan,Sarah F. Mowbray,Robert M. Strieter,Veit J. Erpenbeck,Dave Singh	2019	25
4	Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: A randomized, double‐blind, placebo‐controlled study Martin Metz,Rebecca I. Torene,Sérgio Kaiser,Michael T. Beste,Petra Staubach,Andrea Bauer,Randolf Brehler,Janine Gericke,Martin Letzkus,Nicole Hartmann,Veit J. Erpenbeck,Marcus Maurer	2018	26
5	U-BIOPRED: evaluation of the value of a public–private partnership to industry John Riley,Veit J. Erpenbeck,John G. Matthews,Cécile Holweg,Christopher Compton,Wolfgang Seibold,T. W. Higenbottam,Scott Wagers,Anthony Rowe,David Myles	2018	11
6	Safety, tolerability and pharmacokinetics of QAV680, an oral CRTh2 antagonist, in healthy subjects Veit J. Erpenbeck,Rainard Fuhr,Gerald Dubois,Sheryl Perry	2014	0
7	Efficacy and safety of 10 day treatment with the CRTh2 antagonist QAV680 evaluated in patients with allergic rhinitis in an environmental exposure chamber Veit J. Erpenbeck,Ann Marie Salapatek,Piyush M. Patel,Johanne Sanni,Gerald Dubois,Ping Zhou,Sheryl Perry,Michael Larbig	2014	3
8	QAV680, cetirizine and their combination reduce nasal symptoms in patients with intermittent allergic rhinitis in an environmental exposure chamber Veit J. Erpenbeck,Anne Marie Salapatek,Piyush M. Patel,Deanne Carew,Gerald Dubois,Sheryl Perry,Michael Larbig	2014	2
9	Safety, tolerability and pharmacokinetics of an oral competitive reversible CRTh2 antagonist, QAW039, in healthy subjects Veit J. Erpenbeck,Eva Vets,Lien Gheyle,Wande Osuntokun,Michael Larbig,Srikanth Neelakantham,Gerald Dubois,Sheryl Perry	2014	3
10	Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table Oliver Kornmann,Henrik Watz,Rainard Fuhr,Norbert Krug,Veit J. Erpenbeck,Guenther Kaiser	2014	27
11	Surfactant Protein D modulates allergen particle uptake and inflammatory response in a human epithelial airway model Carsten Schleh,Barbara Rothen‐Rutishauser,Fabian Blank,Hans D Lauenstein,Matthias Nassimi,Norbert Krug,Armin Braun,Veit J. Erpenbeck,Peter Gehr,Jens M. Hohlfeld	2012	18
12	Allergen particle binding by human primary bronchial epithelial cells is modulated by surfactant protein D Carsten Schleh,Veit J. Erpenbeck,Carla Winkler,Hans D Lauenstein,Matthias Nassimi,Armin Braun,Norbert Krug,Jens M. Hohlfeld	2010	12
13	Pharmacological Targeting of Anaphylatoxin Receptors during the Effector Phase of Allergic Asthma Suppresses Airway Hyperresponsiveness and Airway Inflammation Ralf Baelder,Barbara Fuchs,Wilfried Bautsch,Joerg Zwirner,Jörg Köhl,Heinz G. Hoymann,Thomas Glaab,Veit J. Erpenbeck,Norbert Krug,Armin Braun	2005	90
14	Local nitric oxide levels reflect the degree of allergic airway inflammation after segmental allergen challenge in asthmatics Veit J. Erpenbeck,Rudolf A. Jörres,Marc Discher,Harald Krentel,Dimitrios Tsikas,Birgit Luettig,Norbert Krug,Jens M. Hohlfeld	2005	12
15	Increased Expression of Interleukin-9 Messenger RNA After Segmental Allergen Challenge in Allergic Asthmatics Veit J. Erpenbeck,Jens M. Hohlfeld,Marc Discher,Harald Krentel,Andreas Hagenberg,Armin Braun,Norbert Krug	2003	29
16	Increased Messenger RNA Expression of c-maf and GATA-3 After Segmental Allergen Challenge in Allergic Asthmatics Veit J. Erpenbeck,Jens M. Hohlfeld,Marc Discher,Harald Krentel,Andreas Hagenberg,Armin Braun,Norbert Krug	2003	16
17	Segmental allergen challenge in patients with atopic asthma leads to increased IL-9 expression in bronchoalveolar lavage fluid lymphocytes Veit J. Erpenbeck,Jens M. Hohlfeld,Brunhild Volkmann,Andreas Hagenberg,Henning Geldmacher,Armin Braun,Norbert Krug	2003	121
18	Divergence in urinary 8-iso-PGF2α (iPF2α-III, 15-F2t-IsoP) levels from gas chromatography–tandem mass spectrometry quantification after thin-layer chromatography and immunoaffinity column chromatography reveals heterogeneity of 8-iso-PGF2α Dimitrios Tsikas,Edzard Schwedhelm,Maria-Theresia Suchy,Jonas Niemann,Frank‐Mathias Gutzki,Veit J. Erpenbeck,Jens M. Hohlfeld,Andrzej Surdacki,Jürgen C. Frölich	2003	78
19	Complement Factors C3a and C5a are Increased in Bronchoalveolar Lavage Fluid after Segmental Allergen Provocation in Subjects with Asthma Norbert Krug,Thomas Tschernig,Veit J. Erpenbeck,Jens M. Hohlfeld,Jörg Köhl	2001	150
20	Interleukin 16 and T-cell Chemoattractant Activity in Bronchoalveolar Lavage 24 Hours after Allergen Challenge in Asthma Norbert Krug,William W. Cruikshank,Thomas Tschernig,Veit J. Erpenbeck,Kerstin Balke,Jens M. Hohlfeld,H Fabel	2000	31

About Veit J. Erpenbeck

Veit J. Erpenbeck is a scholar working on Immunology and Allergy, Physiology and Immunology, having authored 41 papers that have together received 1.7k indexed citations. Recurring topics across this work include Asthma and respiratory diseases (25 papers), Allergic Rhinitis and Sensitization (16 papers), IL-33, ST2, and ILC Pathways (9 papers), Eosinophilic Esophagitis (5 papers), Respiratory and Cough-Related Research (4 papers), Receptor Mechanisms and Signaling (4 papers), Contact Dermatitis and Allergies (3 papers) and Mast cells and histamine (3 papers). The work is most often cited by research in Immunology and Allergy (429 citations), Physiology (858 citations) and Immunology (589 citations). Veit J. Erpenbeck has collaborated with scholars based in Switzerland, Germany and United States. Frequent co-authors include Norbert Krug, Jens M. Hohlfeld, Armin Braun, Thomas Tschernig, Jörg Köhl, Janice Canvin, Stephen T. Holgate, William W. Busse, Nicola A. Hanania and Philip J. Lowe.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact